OnKure Therapeutics, Inc. Earnings Per Share Disclosure
6. Net Loss Per Share
The Company computes basic loss per share by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share assumes the conversion, exercise or issuance of all potential common stock equivalents, unless the effect of inclusion would be anti-dilutive. For purposes of this calculation, common stock shares to be issued upon if-converted method for the convertible Series C Preferred Stock, if-converted method for the convertible promissory note, exercise of all outstanding stock options and restricted stock units were excluded from the diluted net loss per share calculation for the twelve months ended December 31, 2024 and 2023 because such shares are anti-dilutive.
Anti-dilutive securities outstanding during the period not included in the diluted net loss per share calculation include the following:
|
December 31, |
|
|||||
|
2024 |
|
|
2023 |
|
||
Convertible Series C Preferred Stock |
|
5,191,375 |
|
|
|
6,135,306 |
|
Convertible Promissory Notes |
|
149,650 |
|
|
|
— |
|
Outstanding stock options |
|
2,393,824 |
|
|
|
178,232 |
|
Unvested restricted stock units |
|
213,254 |
|
|
|
214,436 |
|
Unreleased restricted stock units assumed in the Merger |
|
17,000 |
|
|
|
— |
|
|
|
7,965,103 |
|
|
|
6,527,974 |
|
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2024 | Mar 10, 2025 | Showing above |
| 2023 | Mar 28, 2024 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.